TO HEART 2 GUIDE HOW TO
TO HEART 2 GUIDE TRIAL

Much of the confusion and fog surrounding this topic comes from the apples to oranges to bananas comparisons. In simple terms, Zone 2 training refers to setting specific parameters to your training session that keep you in an aerobic state. Before we dive in, I ask that you take a moment to gather up what you’ve been told about Zone 2, Zone 3, Zone XYZ, lactate, whether cavemen ate bread (kidding), and set it to the side so we can approach this from a clean slate.

TO HEART 2 GUIDE HOW TO

My goal is to dismiss semantics and scientific jargon in the name of arming you with a clear and concise breakdown of how to use heart rate based training to develop your aerobic system.

TO HEART 2 GUIDE TRIAL

Trial Registration: ClinicalTrials.Welcome to the CrossFitters guide to Zone 2 training.

Dr Ahmad is a consultant for Amgen, Cytokinetics, Relypsa, and Novartis. Dr O’Connor reports receiving grant support from Roche Diagnostics and the National Institutes of Health. Dr Fiuzat reports receiving grant support from the National Institutes of Health and Roche Diagnostics. Dr Felker has received research grants from the National Heart, Lung, and Blood Institute, American Heart Association, Amgen, Bayer Merck, Cytokinetics, and MyoKardia he has acted as a consultant to Novartis, Amgen, BMS, Cytokinetics, Medtronic, Cardionomic, Innolife, Boehringer Ingelheim, Abbott, Eidos Therapeutics, Reprieve, and Sequana and has served on clinical end point committees/data and safety monitoring boards for Amgen, Merck, Medtronic, EBR Systems, V-Wave, LivaNova, and Rocket Pharma. Dr Desai works under contract with the Centers for Medicare and Medicaid Services to develop and maintain performance measures used for public reporting and pay-for-performance programs he reports research grants and consulting for Amgen, AstraZeneca, Boehringer Ingelheim, Cytokinetics, Medicines Company, Relypsa, Novartis, and scPharmaceuticals. Dr Januzzi is a Trustee of the American College of Cardiology has received grant support from Roche Diagnostics, Novartis Pharmaceuticals, and Applied Therapeutics and consulting income from Abbott, Janssen, Novartis, and Roche Diagnostics and participates in clinical end point committees/data and safety monitoring boards for Abbott, AbbVie, Amgen, CVRx, Janssen, MyoKardia, and Takeda. Dr Friedman has received educational grants from Boston Scientific, Medtronic, and Abbott research grants from the American Heart Association, National Cardiovascular Data Registry, Boston Scientific, Abbott, Medtronic, Merit Medical, and Biosense Webster and consulting fees from Abbott and AtriCure. Potential Competing Interests: Dr Freeman reports salary support from the American College of Cardiology National Cardiovascular Data Registry and the National Heart, Lung, and Blood Institute and consulting/advisory board fees from Boston Scientific, Medtronic, Janssen Pharmaceuticals, and Biosense Webster.

To heart 2 guide